B
Bayard D. Clarkson
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 383
Citations - 27729
Bayard D. Clarkson is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Leukemia & Bone marrow. The author has an hindex of 84, co-authored 383 publications receiving 27241 citations. Previous affiliations of Bayard D. Clarkson include University of Texas Southwestern Medical Center & Kettering University.
Papers
More filters
Journal ArticleDOI
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
Thomas Schindler,William Bornmann,Patricia Pellicena,W. Todd Miller,Bayard D. Clarkson,John Kuriyan +5 more
TL;DR: The results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.
Structural Mechanism for STI-571 Inhibition of Abelson
Thomas Schindler,William G. Bornmann,Patricia Pellicena,W. Todd Miller,Bayard D. Clarkson,John Kuriyan +5 more
TL;DR: The crystal structure of the catalytic domain of the Abelson tyrosine kinase (Abl) complexed to a variant of STI-571 is reported in this paper.
Journal ArticleDOI
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Joseph E. Sokal,EB Cox,Michele Baccarani,Tura S,German A. Gomez,Judith E. Robertson,CY Tso,Thomas J. Braun,Bayard D. Clarkson,Francisco Cervantes +9 more
TL;DR: The prognostic significance of disease features recorded at the time of diagnosis was examined among 813 patients with Philadelphia chromosome- positive, nonblastic chronic granulocytic leukemia (CGL) collected from six European and American series, and it should be possible to identify a lower risk group of patients with a 2-yr survival of 90%, subsequent risk averaging somewhat less than 20%/yr and median survival of 5 yr.
ComponentDOI
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
Bhushan Nagar,William G. Bornmann,Patricia Pellicena,Thomas Schindler,Darren R. Veach,W. Todd Miller,Bayard D. Clarkson,John Kuriyan +7 more
TL;DR: In this article, the authors report crystal structures of the kinase domain of Abl in complex with two small molecule inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).
Journal ArticleDOI
Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
Janice Gabrilove,Ann A. Jakubowski,Ann A. Jakubowski,Howard I. Scher,Howard I. Scher,Cora N. Sternberg,Cora N. Sternberg,George Y. Wong,George Y. Wong,John Grous,John Grous,Alan Yagoda,Alan Yagoda,K. Fain,K. Fain,Malcolm A.S. Moore,Malcolm A.S. Moore,Bayard D. Clarkson,Bayard D. Clarkson,Herbert F. Oettgen,Herbert F. Oettgen,Kirby Alton,Kirby Alton,Karl Welte,Karl Welte,Lawrence M. Souza,Lawrence M. Souza +26 more
TL;DR: It is demonstrated that rhG-CSF is a potent stimulus of normal neutrophil proliferation and maturation and its administration can reduce both the hematopoietic and oral toxicity of chemotherapy.